Up to 95% of pancreatic cancer patients have a KRAS mutation, long thought undruggable. Dr. Eileen O'Reilly of Memorial Sloan Kettering explains what changed and what Rasonque™ (daraxonrasib) means for patients. 🎧 youtu.be/vu0CWLzsusU #PancChat #OncSky